6 November 2024 in Nature Cell Biology
RNA modification has emerged as an important epigenetic mechanism that controls abnormal metabolism and growth in acute myeloid leukaemia (AML). However, the roles of RNA N4-acetylcytidine (ac4C) modification in AML remain elusive. Here, we report that ac4C and its catalytic enzyme NAT10 drive leukaemogenesis and sustain self-renewal of leukaemic stem cells/leukaemia-initiating cells through reprogramming serine metabolism. Mechanistically, NAT10 facilitates exogenous serine uptake and de novo biosynthesis through ac4C-mediated translation enhancement of the serine transporter SLC1A4 and the transcription regulators HOXA9 and MENIN that activate transcription of serine synthesis pathway genes. We further characterize fludarabine as an inhibitor of NAT10 and demonstrate that pharmacological inhibition of NAT10 targets serine metabolic vulnerability, triggering substantial anti-leukaemia effects both in vitro and in vivo. Collectively, our study demonstrates the functional importance of ac4C and NAT10 in metabolism control and leukaemogenesis, providing insights into the potential of targeting NAT10 for AML therapy.
6 May 2021 in Cancer Communications
As one of the most studied ribonucleic acid (RNA) modifications in eukaryotes, N 6 ‐methyladenosine (m 6 A) has been shown to play a predominant role in controlling gene expression and influence physiological and pathological processes such as oncogenesis and tumor progression. Writer and eraser proteins, acting opposite to deposit and remove m 6 A epigenetic marks, respectively, shape the cellular m 6 A landscape, while reader proteins preferentially recognize m 6 A modifications and mediate fate decision of the methylated RNAs, including RNA synthesis, splicing, exportation, translation, and stability. Therefore, RNA metabolism in cells is greatly influenced by these three classes of m 6 A regulators. Aberrant expression of m 6 A regulators has been widely reported in various types of cancer, leading to cancer initiation, progression, and drug resistance. The close links between m 6 A and cancer shed light on the potential use of m 6 A methylation and its regulators as prognostic biomarkers and drug targets for cancer therapy. Given the notable effects of m 6 A in reversing chemoresistance and enhancing immune therapy, it is a promising target for combined therapy. Herein, we summarize the recent discoveries on m 6 A and its regulators, emphasizing their influences on RNA metabolism, their dysregulation and impacts in diverse malignancies, and discuss the clinical implications of m 6 A modification in cancer.
1 June 2020 in Acta Biochimica et Biophysica Sinica
Clear cell renal cell carcinoma (ccRCC) is a common malignancy of the genitourinary system and is associated with high mortality rates. However, the molecular mechanism of ccRCC pathogenesis is still unclear, which translates to few effective diagnostic and prognostic biomarkers. In this study, we conducted a bioinformatics analysis on three Gene Expression Omnibus datasets and identified 437 differentially expressed genes (DEGs) related to ccRCC development and prognosis, of which 311 and 126 genes are respectively down-regulated and up-regulated. The protein-protein interaction network of these DEGs consists of 395 nodes and 1872 interactions and 2 prominent modules. The Staphylococcus aureus infection and complement and coagulation cascades are significantly enriched in module 1 and are likely involved in ccRCC progression. Forty-two hub genes were screened, of which von Willebrand factor, TIMP metallopeptidase inhibitor 1, plasminogen, formimidoyltransferase cyclodeaminase, solute carrier family 34 member 1, hydroxyacid oxidase 2, alanine-glyoxylate aminotransferase 2, phosphoenolpyruvate carboxykinase 1, and 3-hydroxy-3-methylglutaryl-CoA synthase 2 are possibly related to the prognosis of ccRCC. The differential expression of all nine genes was confirmed by quantitative real-time polymerase chain reaction analysis of the ccRCC and normal renal tissues. These key genes are potential biomarkers for the diagnosis and prognosis of ccRCC and warrant further investigation.
31 August 2026 in Genomics, Proteomics & Bioinformatics
RNA-binding proteins (RBPs) play critical roles in regulating the maintenance and differentiation of embryonic stem cells. A critical step in understanding the functions of RBPs is the identification of their bound RNA transcripts. To achieve this, we developed an inducible strategy termed RNA-Editing-Based-RNA-seq (REB-seq) coupled with machine learning to capture the potential RNA targets bound by the RBPs-of-interest. By fusing RBPs to the catalytic domain of ADAR or APOBEC1, which mediates the A-to-I (A-to-G) or C-to-U (C-to-T) editing, respectively, REB-seq enables transcriptome-wide identification of RBP-bound RNAs without high-quality antibodies. Using REB-seq, we characterized the mRNAs bound by the N6-methyladenosine (m6A) readers IGF2BP1, IGF2BP2, and IGF2BP3 in human embryonic stem cells. Coupling REB-seq analysis with machine learning further improves the accuracy of target RNA characterization. Furthermore, REB-seq identifies associated single nucleotide polymorphisms that may affect the RBP binding and imply disease pathogenesis. Collectively, REB-seq coupled with machine learning provides a robust and accessible approach for profiling allele-specific RNA transcripts bound by RBPs-of-interest.